Pall — FY2013 Earnings Presentation
23 slides from Pall's earnings presentation, Aug 29, 2013
Slide 1: Q4 and Full Year FY 2013 Financial Results
Better Lives. Better Planet.SM © 2013 Pall Corporation Q4 and Full Year FY 2013 Financial Results August 29, 2013 Exhibit 99.2
Slide 2: Forward-looking statements
2 The matters discussed in this presentation contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Results for the third quarter of fiscal year 2013 are preliminary until the Company's Form 10-K is filed with the Securities and Exchange Commission o
Slide 3: Conference Call Replay Info
3 Conference Call Replay Info Toll-Free: 855.859.2056 International: 404.537.3406 Conference ID: 26704892 Internet: www.pall.com/investor
Slide 4: FY 2013 Summary
4 FY 2013 Summary FY 2013 pro forma EPS up 9% on 1% revenue (ex-FX) growth 2013: Good evolution in a multi-year journey – Operational momentum continues – R&D translating to commercial wins – Cost saving initiatives improving bottom line – Systems rationalization complete Caution on the macro
Slide 5: Financial Overview
5 $722 $717 $2,672 $2,648 $- $500 $1,000 $1,500 $2,000 $2,500 $3,000 Revenue % Growth Ex-FX Q4 Full Year Financial Overview (1) Includes estimated Japanese Yen transactional FX impact 0f ~$0.03. Dollars in millions, except EPS data A reconciliation of Non-GAAP Financial Measures in this presentation
Slide 6: Sales by Segment
6 Fourth Quarter Life Sciences Consumables $316 / +4% Industrial Consumables $284 / -4% Industrial Systems $79 / -9% Life Sciences Systems $38 / +33% 40% 44% 11% 5% FY 2013 Sales by Segment Life Sciences Consumables $1,198 / +8% Industrial Consumables $1,097 / -3% Full Year Industrial Systems $242 /
Slide 7: Life Sciences Segment Performance
7 Orders Q4 YoY Δ Ex-FX Full Year YoY Δ Ex-FX Consumables $ 315 5% $ 1,226 8% Systems 25 -37% $ 111 2% Total Life Sciences $ 340 0% $ 1,337 8% Sales Q4 YoY Δ Ex-FX Full Year YoY Δ Ex-FX Consumables $ 316 4% $ 1,198 8% Systems 38 33% $ 111 -7% Total Life Sciences $ 354 6% $ 1,309 6% 0% 30% 60% Life S
Slide 8: Industrial Segment Performance
8 46.5% +110 bps 45.4% Industrial Segment Performance Dollars in millions A reconciliation of Non-GAAP Financial Measures in this presentation to their GAAP Counterparts is provided in the Appendix Sales Q4 YoY Δ Ex-FX Full Year YoY Δ Ex-FX Consumables $ 284 -4% $ 1,097 -3% Systems 79 -9% $ 242 -6%
Slide 9: Cash Flow
9 Cash Flow YTD FY13 YTD FY12 Operating Cash Flow 384$ 475$ CapEx (110) (159) Free Cash Flow 274$ 316$ Other Significant Sources/(Uses) of Cash: Proceeds from sale of assets 538$ 27$ Acquisition of businesses (22) (168) Dividends (108) (89) Borrowing/Repayment under Financing Facilities (35) (10) St
Slide 10: FY 2014 Outlook
10 Total Revenue Low to mid single digit growth Segment Revenue Life Sciences: Mid to high single digit growth Industrial: Flat − Modest consumables growth Pro Forma EPS $3.30 – $3.50 Represents growth of 9% – 15% Estimate excludes Discrete Items, future acquisitions and related costs FY
Slide 11: Appendix
Better Lives. Better Planet.SM © 2013 Pall Corporation Appendix
Slide 12: Appendix: Regional Sales
12 $0 $200 $400 $600 $800 $1,000 $1,200 $228 -10% $268 +3% $221 +11% Americas EMEA Asia $849 +2% $1,035 +2% $764 -2% Appendix: Regional Sales Dollars in millions Sales changes exclude FX A reconciliation of Non-GAAP Financial Measures in this presentation to their GAAP Counterparts is provided in th
Slide 13: Appendix: Q4 Earnings from Continuing Operations
13 Appendix: Q4 Earnings from Continuing Operations Reconciliation of Non-GAAP Financial Measures Diluted EPS from continuing operations as reported 0.76$ 0.64$ 2.89$ 2.39$ Discrete Items: ROTC after pro forma tax effect 0.14 0.25 0.28 0.44 Tax Adjustments - (0.01) (0.09) (0.01) Interest Adjustments
Slide 14: Appendix: Q4 Life Sciences Sales By Market & Technology
14 Appendix: Q4 Life Sciences Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Q4 FY13 Q4 FY13 Estimated Impact of FX Q4 FY13 Estimate Excluding FX Q4 FY12 % Change Excluding FX Consumables Sales: BioPharmaceuticals 215,211$ (1,021)$ 216,232$ 204,778$ 5.6% Food & Beverage 4
Slide 15: Appendix: Full Year Life Sciences Sales By Market & Technology
15 Appendix: Full Year Life Sciences Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Full Year FY13 Full Year FY13 Estimated Impact of FX Full Year FY13 Estimate Excluding FX Full Year FY12 % Change Excluding FX Consumables Sales: BioPharmaceuticals 812,328$ (14,920)$ 827,
Slide 16: Appendix: Q4 Industrial Sales By Market & Technology
16 Appendix: Q4 Industrial Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Q4 FY13 Q4 FY13 Estimated Impact of FX Q4 FY13 Estimate Excluding FX Q4 FY12 % Change Excluding FX Consumables Sales: Process Technologies 151,299$ (1,710)$ 153,009$ 151,457$ 1.0% Aerospace 59,417 (
Slide 17: Appendix: Full Year Industrial Sales By Market & Technology
17 Appendix: Full Year Industrial Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Full Year FY13 Full Year FY13 Estimated Impact of FX Full Year FY13 Estimate Excluding FX Full Year FY12 % Change Excluding FX Consumables Sales: Process Technologies 584,125$ (10,974)$ 595,0
Slide 18: Appendix: Q4 Orders by Technology
18 Appendix: Q4 Orders by Technology Reconciliation of Non-GAAP Financial Measures Dollars in thousands Q4 FY13 Q4 FY13 Estimated Impact of FX Q4 FY13 Estimate Excluding FX Q4 FY12 % Change Excluding FX Life Sciences Orders: Consumables 315,043$ (636)$ 315,679$ 299,610$ 5.4% Systems 24,917 (278) 25,
Slide 19: Appendix: Full Year Orders by Technology
19 Appendix: Full Year Orders by Technology Reconciliation of Non-GAAP Financial Measures Dollars in thousands Full Year FY13 Full Year FY13 Estimated Impact of FX Full Year FY13 Estimate Excluding FX Full Year FY12 % Change Excluding FX Life Sciences Orders: Consumables 1,225,836$ (22,349)$ 1,248,1
Slide 20: Appendix: Sales by Region
20 Appendix: Sales by Region Reconciliation of Non-GAAP Financial Measures Q4 FY13 Q4 FY13 Estimated Impact of FX Q4 FY13 Estimate Excluding FX Q4 FY12 % Change Excluding FX Americas 227,977$ (1,586)$ 229,563$ 255,740$ -10.2% Europe 268,263 8,357 259,906 253,396 2.6% Asia 220,578 (15,306) 235,884 21
Slide 21: Appendix: Q4 Operating Profit
21 Appendix: Q4 Operating Profit Reconciliation of Non-GAAP Financial Measures Operating Profit Q4 FY13 Q4 FY12 Life Sciences segment profit 85,757$ 86,121$ Industrial segment profit 68,075 67,552 Total segment profit 153,832$ 153,673$ General corporate expenses (19,377) (14,338) Operating profit 13
Slide 22: Appendix: Full Year Operating Profit
22 Appendix: Full Year Operating Profit Reconciliation of Non-GAAP Financial Measures Operating Profit Full Year FY13 Full Year FY12 Life Sciences segment profit 319,271$ 319,312$ Industrial segment profit 214,798 198,747 Total segment profit 534,069$ 518,059$ General corporate expenses (66,640) (64
Slide 23: Better Lives. Better Planet.
Better Lives. Better Planet.SM © 2013 Pall Corporation www.pall.com/green